Anti-mucin1 aptamer-conjugated chitosan nanoparticles for targeted co-delivery of docetaxel and IGF-1R siRNA to SKBR3 metastatic breast cancer cells

Jafari, R. and Zolbanin, N. M. and Majidi, J. and Atyabi, F. and Yousefi, M. and Jadidi-Niaragh, F. and Aghebati-Maleki, L. and Shanehbandi, D. and Zangbar, M. S. S. and Rafatpanah, H. (2019) Anti-mucin1 aptamer-conjugated chitosan nanoparticles for targeted co-delivery of docetaxel and IGF-1R siRNA to SKBR3 metastatic breast cancer cells. Iranian Biomedical Journal, 23 (1). pp. 21-33.

[img] Text
Anti-mucin1 aptamer-conjugated chitosan nanoparticles for targeted co-delivery of docetaxel and IGF-1R siRNA to SKBR3 metastatic breast cancer cells.pdf

Download (1MB)

Abstract

Background: Targeted co-delivery of siRNA and a chemotherapeutic drug is an attractive approach to cancer drug design and treatment. This study was carried out to design an anti-Mucin1 aptamer (Apt)-conjugated chitosan nanoparticle (NP) for targeted co-delivery of insulin-like growth factor receptor 1 (IGF-1R) Silencer siRNA and docetaxel (DTX) to SKBR3 cells. Methods: Characterization of nano-drugs, cellular uptake of NPs, cell viability, and gene expression studies were evaluated based on metastatic breast cancer cells. Results: The results of this study showed that NPs had spherical and smooth morphology with 110-118 nm in size and had positive zeta potential (12-14 mV). siRNA and DTX were considerably loaded into NPs. The appropriate conjugation of the Apt to the NPs was affirmed by gel electrophoresis. The Apt-conjugated NPs were observed to enhance the cellular uptake of NPs into the SKBR3 cells. Although the combination treatment significantly decreased the cell viability of SKBR3 cells, the augmentative effect was observed when Apt was conjugated to NPs. Furthermore, Apt-conjugated NPs dramatically reduced the genetic expression of IGF-1R, signal transducers and activators of transcription 3 (STAT3), matrix metalloproteinases (MMP9), and vascular growth factor (VEGF). Conclusion: The targeted NPs may augment the targeting of pathways involved in tumorigenesis and metastasis of breast cancer. Therefore, more animal model experiments are needed to further clarify the efficacy and safety of this functionalized nanodrug. DOI: 10.29252/.23.1.21. © 2019, Pasteur Institute of Iran. All rights reserved.

Item Type: Article
Additional Information: Cited By :5 Export Date: 16 February 2020 CODEN: IBJRA Correspondence Address: Rafatpanah, H.; Immunology Research Center, Division of Inflammation and Inflammatory Diseases, Mashhad University of Medical SciencesIran; email: RafatpanahH@mums.ac.ir
Uncontrolled Keywords: Breast cancer therapy Chitosan nanoparticles Docetaxel IGF-1R siRNA MUC1 aptamer aptamer chitosan nanoparticle gelatinase B small interfering RNA somatomedin C receptor STAT3 protein vasculotropin chitosan heparin IGF1R protein, human mucin 1 nanoparticle somatomedin receptor Article cell size cell viability controlled study drug delivery system drug targeting gel electrophoresis gene expression human human cell SK-BR-3 cell line zeta potential animal breast tumor cell survival chemistry CHO cell line Cricetulus drug effect drug release gene expression regulation gene silencing genetics hamster metabolism metastasis particle size pathology serum static electricity tumor cell line ultrastructure Animals Aptamers, Nucleotide Breast Neoplasms Cell Line, Tumor CHO Cells Cricetinae Drug Liberation Gene Expression Regulation, Neoplastic Humans Mucin-1 Nanoparticles Neoplasm Metastasis Receptors, Somatomedin RNA, Small Interfering
Subjects: QW Microbiology and Immunology
Divisions: Mashhad University of Medical Sciences
Depositing User: mr lib1 lib1
Date Deposited: 21 Jun 2020 06:45
Last Modified: 21 Jun 2020 06:45
URI: http://eprints.mums.ac.ir/id/eprint/18428

Actions (login required)

View Item View Item